# Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

> **NCT02172755** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 30 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093

## Key facts

- **NCT ID:** NCT02172755
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2002-08
- **Final completion:** 2002-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172755, "Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02172755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*